NYX-458 is a small molecule commercialized by Aptinyx, with a leading Phase II program in Dementia. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of NYX-458’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NYX-458 is expected to reach an annual total of $43 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NYX-458 is under development for the treatment of mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with lewy bodies. It is administered through oral route and formulated as capsule. The drug candidate acts by targeting N-methyl D-aspartate receptor (NMDAR).
Aptinyx is a pharmaceutical and healthcare company. It discovers and develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include NYX-2925, a therapy for neuropathic pain; NYX-783, for post-traumatic stress disorder (PTSD); and NYX-458, for the treatment of cognitive impairment associated with Parkinson’s disease. Its proprietary chemistry platform helps develop a pipeline of small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors and improves synaptic plasticity. The company’s NMDA receptor modulators are under clinical development as differentiated therapies for depression, and they possess efficacy and safety with the potential to treat various neurologic disorders. Aptinyx is headquartered in Evanston, Illinois, the US.
The company reported revenues of (US Dollars) US$1 million for the fiscal year ended December 2021 (FY2021), a decrease of 36.1% over FY2020. The operating loss of the company was US$74.5 million in FY2021, compared to an operating loss of US$50.8 million in FY2020. The net loss of the company was US$74.9 million in FY2021, compared to a net loss of US$50.1 million in FY2020.
For a complete picture of NYX-458’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.